Filing Details

Accession Number:
0001640334-21-000147
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-20 16:56:45
Reporting Period:
2021-01-14
Accepted Time:
2021-01-20 16:56:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
895464 Yubo International Biotech Ltd YBGJ Electromedical & Electrotherapeutic Apparatus (3845) 113074326
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1828515 Lina Liu Yubo International Biotech Limited
Room 105, Building 5, Xishiku Avenue
Xicheng District, Beijing F4 00000
Cfo, Treasurer And Secretary No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Disposition 2021-01-14 116,697,438 $0.00 0 No 4 D Direct
Class A Common Stock Acquisiton 2021-01-14 13,829,400 $0.00 13,829,400 No 4 P Indirect By Focus Draw Group
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 D Direct
No 4 P Indirect By Focus Draw Group
Footnotes
  1. The shares reported herein were surrendered to the issuer and canceled in connection with an exchange transaction by and among Platinum International Biotech Co., Ltd.("Platinum"),Yubo International Biotech (Beijing) Limited, the Reporting Person and certain other stockholders of Platinum. No cash consideration was paid in connection with surrender and cancellation of the shares.
  2. The shares reported herein were acquired in connection with an exchange transaction by and among Platinum International Biotech Co., Ltd. ("Platinum"), Yubo International Biotech (Beijing) Limited, the Reporting Person and certain other stockholders of Platinum. The Issuer issued the shares reported herein to the Reporting Person in exchange for the Reporting Person's equity interest in Platinum. No cash consideration was paid in connection with the exchange transaction.
  3. The shares are held by Focus Draw Group, of which the reporting person is the sole director. The Reporting Person disclaims beneficial ownership of the securities except to the extent of her pecuniary interest therein.